Sophiris Bio, Inc. Common Stock, also called Sophiris Bio, is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. Read More The firm develops PRX302 as a treatment for the symptoms of benign prostatic hyperplasia which is a non cancerous enlargement of the prostate gland that causes a restriction in urine flow from the urethra resulting in lower urinary tract symptoms. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.